335 related articles for article (PubMed ID: 28365441)
1. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
[TBL] [Abstract][Full Text] [Related]
2. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
3. JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.
Wolf A; Eulenfeld R; Gäbler K; Rolvering C; Haan S; Behrmann I; Denecke B; Haan C; Schaper F
JAKSTAT; 2013 Jul; 2(3):e24574. PubMed ID: 24069558
[TBL] [Abstract][Full Text] [Related]
4. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
[TBL] [Abstract][Full Text] [Related]
6. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
7. Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.
Fukumoto T; Kubota Y; Kitanaka A; Yamaoka G; Ohara-Waki F; Imataki O; Ohnishi H; Ishida T; Tanaka T
Cell Signal; 2009 Dec; 21(12):1775-83. PubMed ID: 19665053
[TBL] [Abstract][Full Text] [Related]
8. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
9. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
11. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
12. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
[No Abstract] [Full Text] [Related]
13. An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2
Rabadan Moraes G; Pasquier F; Marzac C; Deconinck E; Damanti CC; Leroy G; El-Khoury M; El Nemer W; Kiladjian JJ; Raslova H; Najman A; Vainchenker W; Marty C; Bellanné-Chantelot C; Plo I
Br J Haematol; 2022 Jul; 198(1):131-136. PubMed ID: 35355248
[TBL] [Abstract][Full Text] [Related]
14. Aberrant signal transduction pathways in myeloproliferative neoplasms.
Kota J; Caceres N; Constantinescu SN
Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
[TBL] [Abstract][Full Text] [Related]
15. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
16. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
17. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
18. MAPK-induced Gab1 translocation to the plasma membrane depends on a regulated intramolecular switch.
Wolf A; Eulenfeld R; Bongartz H; Hessenkemper W; Simister PC; Lievens S; Tavernier J; Feller SM; Schaper F
Cell Signal; 2015 Feb; 27(2):340-52. PubMed ID: 25460044
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Guerini V; Barbui V; Spinelli O; Salvi A; Dellacasa C; Carobbio A; Introna M; Barbui T; Golay J; Rambaldi A
Leukemia; 2008 Apr; 22(4):740-7. PubMed ID: 18079739
[TBL] [Abstract][Full Text] [Related]
20. A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.
Casolari DA; Nguyen T; Butcher CM; Iarossi DG; Hahn CN; Bray SC; Neufing P; Parker WT; Feng J; Maung KZY; Wee A; Vidovic L; Kok CH; Bardy PG; Branford S; Lewis ID; Lane SW; Scott HS; Ross DM; D'Andrea RJ
Sci Rep; 2017 May; 7(1):2467. PubMed ID: 28550306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
